ARF inhibits the growth of p53 nullizygous human tumours in nude mice and induces the regression of p53 À/À established tumours. In these experiments, tumoral regression was associated with inhibition of cell proliferation as well as induction of apoptosis confirming the data obtained in cell lines.
Introduction
The INK4A/ARF locus encodes two structurally distinct proteins, p16
INK4a and ARF, translated from alternatively spliced mRNAs (Quelle et al., 1995; Sherr, 1998) . Both products are expressed in response to inappropriate proliferative signals, and activate pivotal pathways implicated in cell-cycle control and tumour suppression (Chin et al., 1998; Sherr, 1998 Sherr, , 2001 ). The cyclin-dependent kinase inhibitor (CDK-I) p16
INK4a prevents phosphorylation and functional inactivation of the retinoblastoma (RB) protein by cyclin-dependent kinases (Serrano et al., 1993) . On the other hand, ARF protects against cellular transformation and immortalization by activating the p53 tumour suppressive protein (Sherr, 1998) . Expression of ARF is induced in response to activated oncogenes such as Ras (Serrano et al., 1997; Palmero et al., 1998) , c-myc , E1A (de Stanchina et al., 1998) , Abl (Radfar et al., 1998; Cong et al., 1999) and E2F-1 Dimri et al., 2000) as well as during replicative senescence (Sherr, 1998) . Since ARF-null mice are highly tumour prone (Kamijo et al., 1997) and die early in life (Kamijo et al., 1999) , ARF has been proposed to be most important in tumour surveillance.
Consistent with its role as a tumour suppressor, ARF can induce cell-cycle arrest in both G 1 and G 2 phases and/or cell death (Quelle et al., 1995; Kamijo et al., 1997; Stott et al., 1998) . Until recently, the growthsuppressive function of ARF was related to its ability to stabilize p53 leading to the transcriptional activation of well-known p53-target genes such as p21 WAFI or 14.3.3s (Weber et al., 2002) . However, recent data have pointed to additional p53-independent ARF functions on cell growth, but the mechanisms involved remain unclear. In murine systems, p19 ARF can suppress the colony formation of p53 À/À cells by affecting the RB pathway (Carnero et al., 2000) . Furthermore, mice lacking both p53 and p19 ARF develop a wider spectrum of tumours than animals lacking either gene alone, and reintroduction of p19 ARF in mouse embryo fibroblasts (MEF) lacking p53, MDM2 and p19 ARF induces cell growth inhibition (Weber et al., 2000) . In humans, the p53-independent ARF activity has been recently ascribed to its ability to impede S-phase progression (Yarbrough et al., 2002) and to induce p53 and Bax-independent apoptosis (Hemmati et al., 2002) .
Since we have previously showed that human p14 ARF can induce growth inhibition of p53-null cells (Eymin et al., 2001) , we were interested in better characterizing the pathway(s) involved in the p53-independent functions of p14 ARF . To this aim, we transiently or stably expressed p14
ARF in human carcinoma cell lines lacking functional p53. Our data show that p14 ARF induces a transient G 2 arrest followed by apoptosis in these p53-deprived cells. This G 2 arrest correlates with the inhibition of CDC2 activity, inactivation of CDC25C phosphatase, a major upstream regulator of CDC2 and induction of the CDK-I p21 WAFI . On the other hand, apoptosis is associated with the activation of procaspase-3 and poly-ADP ribose polymerase (PARP) cleavage. Importantly, we also demonstrate that p14 ARF inhibits the growth and induces the regression of p53 nullizygous human tumours established in nude mice through the inhibition of cell proliferation and induction of apoptosis, demonstrating the 'in vivo' relevance of our data.
Results

p14
ARF induces cell-cycle arrest in transiently transfected p53-deficient cells
In order to investigate the p53-independent functions of p14 ARF , we transienly transfected two p53-deficient human cell lines derived from bronchioloalveolar lung adenocarcinoma using a full-length p14 ARF expression vector. In these cell lines, p53 was inactivated either by homozygous deletion (H358 cells) or single point mutation (H322 cells). In both cell lines, p14 ARF strongly inhibited cell growth after 7 days of G418 selection, as a 50% decrease in cell number was observed upon p14 ARF transfection as compared to cells transfected with the empty vector (Figure 1a) . In these cells, p14
ARF was expressed in the nucleus where it resided predominantly in the nucleoli (Figure 1b) . In addition, dual-colour flow cytometry revealed that both H358 and H322 cells accumulated with a G 2 /M DNA content when transfected with p14 ARF . Since on visual observation there was no evidence of increased mitotic cells content in this population (data not shown), this pattern is likely to represent a G 2 arrest. Altogether, these results demonstrate the ability of human p14 ARF to inhibit cell growth Figure 1 p14 ARF inhibits cell growth and induces G 2 arrest in transiently transfected p53-null cell lines. (a) H322 and H358 cells were transfected with either control pcDNA3.1 (filled bars) or pcDNA-p14 ARF (hatched bars). After 1 week of G418 selection, the remaining adherent cells were counted. In each case, the number of cells transfected with empty vector (control) was normalized to 100%. Results are the means of three independent experiments performed in duplicate. Bars, s.d ARF -inducible clones in the H358 cell line using the doxycyclin-inducible expression system (Tet-On). Of note, p14
ARF is expressed at a low level in H358 cells (Figure 1a ). Several stable transfectant clones were obtained and further analyses were performed on four of them. Since all clones were found to give similar results, representative data of only clones 19 and 38 are presented here. As shown in Figure 2a , a strong expression of p14 ARF was detected after 24 h of doxycyclin induction, which persisted even after 9 days of continuous induction. In contrast, little or no expression of the exogenous p14 ARF was observed in the uninduced state (Figure 2a ). In these stable (Figure 2b ). As shown in Figure 2c (upper panels), a strong cell growth inhibition was observed upon 9 days of p14 ARF induction in both clones. This growth inhibition was significant as early as 72 h after doxycyclin induction in clone 19, while 6 days were necessary for clone 38 (Figure 2c , lower panels). Growth inhibition was not detected in an empty Tet-On control clone, even in the presence of doxycyclin. Since on the basis of Western blot and immunofluorescence analyses, expression of p14 ARF was lower in clone 38 than in clone 19 (data not shown), the differences of inhibition kinetic between clones 19 and 38 were likely related to the different p14 ARF expression levels between the two clones. Consistent with these time course studies of cell growth inhibition, a G 2 /M arrest was observed following 72 h of doxycyclin induction in clone 19, and 6 days in clone 38 (Figure 2d ). Again, no increase in mitotic cells content was detected in these populations based on visual observation, in agreement with G 2 -arrested cells. Interestingly, we noticed the presence of cells with a DNA content greater than 4n upon p14 ARF induction (data not shown). Taken together, these results confirm, in stable transfectant clones, the ability of p14 ARF to induce a G 2 arrest in p53-independent manner.
Modulation of cell-cycle protein expression associated with p14 ARF -induced G 2 arrest
As entry in mitosis is timely controlled by the cyclin B 1 / CDC2 complex (Figure 3a ; Weinert, 1997; O'Connell et al, 2000; Takizawa and Morgan, 2000) , we analysed the ability of p14 ARF to modulate its activity. Cyclin B 1 / CDC2 complexes were recovered by immunoprecipitation using anti-CDC2 antibody and their ability to phosphorylate histone H1 'in vitro' was tested in p14 ARF -induced cells. A strong inhibition of cyclin B 1 /CDC2 activity was observed in p14 ARF -expressing cells as compared to uniduced cells (Figure 3b) . Consistent with our cell-cycle data (Figure 2d ), this inhibition was observed after 72 h or 6 days of p14 ARF induction, and persisted during 6 or 9 days in clones 19 and 38, respectively (Figure 3b ). Under the same conditions, we did not detect any significant changes in cyclin B 1 and CDC2 expression levels in p14 ARF -induced cells using immunoblotting when compared to uninduced cells ( Figure 3c ) and to H358/Tet-On control cells (data not shown).
Before mitosis, cyclin B1/CDC2 complexes are maintained in an inactive state by phosphorylation of CDC2 on its Thr14 and Tyr15 residues (Figure 3a ; Norbury et al., 1991; Coleman and Dunphy, 1994; Ye et al., 1996; Blasina et al., 1997) . Dephosphorylation of both residues causes the activation of CDC2 and pushes the cells toward mitosis (for a review see Takizawa and Morgan, 2000) In addition, full activation of CDC2 also requires the phosphorylation of a conserved threonine residue (Thr 161) (Russo et al., 1996; Draetta, 1997 ). CDC2 phosphorylation status was then examined using specific antibodies recognizing either Tyr15-or Thr161 phosphorylated residues. As a specific phospho-Tyr14 antibody was not available, CDC2-P Thr14 status could not be studied. As compared to uninduced cells, a marked decrease of CDC2-P Thr161 level was observed in p14 ARF -expressing cells, suggesting that CDC2 was hypophosphorylated on this residue (Figure 3c ). In contrast, the same apparent level of CDC2-P Tyr15 was detected in both cases (with or without doxycyclin induction; Figure 3c ). As dephosphorylation of CDC2 at tyrosine 15 occurs only in mitotic cells, the level of CDC2-P Tyr15 in a population of asynchronous cells, which contains few mitotic cells, is expected to be high. Therefore, we cannot exclude that this could mask an increased level of phosphorylated CDC2 at Tyr15 residue in the population of p14 ARF -expressing cells principally arrested in G 2 . Taken together, these results suggest that p14 ARF maintains CDC2 into an inactive state, dephosphorylated at Thr161 residue.
Then, we investigated the status of some upper regulators of the cyclin B 1 /CDC2 complexes. At the onset of mitosis, dephosphorylation of both Thr14 and Tyr15 residues on CDC2 is regulated by the CDC25C phosphatase ( Figure 3a ; Kumagai and Dunphy, 1991; Millar et al., 1991; Strausfeld et al., 1991) . CDC25C activity is itself controlled by a complex set of activatory/inhibitory phosphorylations (for a review see Takizawa and Morgan, 2000) . Throughout the cell cycle, except in mitosis, CDC25C is maintained inactivated by phosphorylation on its Ser216 residue that creates a binding site for small phosphoserine-binding proteins called 14-3-3, which inactivate CDC25C by sequestration into the cytoplasm (Peng et al., 1997; Takizawa and Morgan, 2000) . Inp14
ARF -expressing cells, we detected a slight decrease in CDC25C protein level, which was not observed in the H358/Tet-On control cells in the same conditions (data not shown), as well as increase of its inactive phosphorylated form at Ser216 (Figure 3c,d ). This effect was specific for CDC25C as the level of CDC25B and 14.3.3s proteins did not appear to vary (data not shown). These data strongly suggest that p14 ARF inactivates CDC25C by reducing its total expression level and increasing its inactive phosphorylated form. Furthermore and consistent with a biological inactivation, a cytoplasmic accumulation of CDC2, CDC2-P Tyr15 and CDC25C-P Ser216 was observed in p14 ARF -expressing cells (Figure 3e ). In contrast, such accumulation never occurred in uninduced cells or in H358/Tet-On control cells in agreement with the property of these proteins to shuttle continuously from the cytoplasm to the nucleus of proliferating cells. Finally, as CDC2 activity and phosphorylation status can also be controlled by the p21 WAFI CDK-inhibitors family (Harper et al., 1995; Dulic et al., 1998; Niculescu et al., 1998; Smits et al., 2000) , expression of some of them was analysed. An increase of p21 WAFI expression level was detected in p14 Hydroxyurea (HU) treatment was carried out to block the cells in late G 1 and S phase of the cell cycle, allowing a more precise analysis of cellular DNA content in the late stages of the cell cycle after block release, particularly between S and mitosis. In these experiments, Figure 3 Modulation of proteins regulating the G 2 /M transition in p14 ARF -arrested cells. (a) Molecular mechanisms controlling the activation of CDC25C and cyclin B 1 /CDC2 at the onset of mitosis. Briefly, in response to proliferative signals, the CDC25C phosphatase is activated by dephosphorylation of its Ser216 residue resulting in its dissociation from 14.3.3 protein and passage into the nucleus. Complete activation of CDC25C also requires extensive phosphorylation of its amino terminus. Following activation, CDC2 is dephosphorylated onto its inhibitory Tyr15 and Thr14 residues by CDC25C and Phosphorylated onto its activatory Thr161 residue by the CDK-activating kinase CAK leading to the activation of cyclin B 1 /CDC2 complexes. Additional phosphorylations of cyclin B 1 and modifications of the subcellular localization of the cyclin B 1 /CDC2 complexes also ensure passage into mitosis and have not been represented here. (b) CDC2-mediated histone H1 phosphorylation was visualized at the indicated times in both uninduced (DoxÀ) or induced (Dox+) clones, using an 'in vitro' kinase assay. (c) Pattern of expression of the indicated proteins using Western blotting in both clones in the presence (Dox+) or absence (DoxÀ) of doxycyclin. Actin was used as a loading control. (d) Quantification of CDC25C expression level by densitometry in uninduced (DOXÀ or induced (DOX+) clones. Results were expressed as a CDC25C/actin ratio, which was arbitrarily normalized to a 100% expression level in uninduced cells (DOXÀ) at each time studied. (e) Cytoplasmic expression of CDC2, CDC2-P Tyr15 and CDC25-P Ser216 products in uninduced (DoxÀ) or induced (Dox+) clones using Western blotting of a cytoplasmic protein extract p53-independent functions of p14 ARF B Eymin et al p14 ARF was induced 24 h before HU block. As shown in Figure 4a and b, uninduced control cells accumulated with a G 2 /M DNA content until 9 h after block release and started to enter mitosis about 13 h after replating in fresh medium. At 24 h after the release, they were predominantly in G 0 /G 1 (Figure 4a, b) . In contrast, and consistent with a G 2 /M arrest, a continuous accumulation of P14 ARF -induced cells in G 2 /M phases of the cell cycle was observed between 9 and 13 h, and persisted even 24 h (Figure 4a , b) and 48 h (data not shown) after the release. As expected, accumulation of control uninduced cells in G 2 /M 13 h after the block release correlated with a slight upregulation of cyclin B 1 and CDC2, whereas CDC25C protein level did not change (Figure 4c ). At this time, and consistent with passage through mitosis, CDC25C was dephosphorylated at Ser t16 and CDC2 was activated by dephosphorylation at Tyr15 and phosphorylation at Thr161 residues ( Figure 4c ). In these control cells, p21 WAFI was never induced. In contrast, although P14 ARF -expressing cells also accumulated with a G 2 /M DNA content 13 h after the block release, CDC2 remained phosphorylated on Tyr15 and hypophosphorylated on Thr161 residues (Figure 4c ). These data suggest that CDC2 was in an Figure 4 p14 ARF inhibits the G 2 /M phase transition in HU-synchronized cells. H358/Tet-On/ p14 ARF clone 19 was pretreated during 24 h with (Dox+) or without (DoxÀ) 1 mg/ml doxycyclin and further influenced during 24 h in the presence of 1 mm hydroxyurea (HU). HU block was then released and cells were cultured in fresh medium with (Dox+) or without (DoxÀ) doxycyclin. At 6 h (T6), 9 h (T9), 13 h (T13) and 24 h (T24) after the block release, the cells were collected and processed for dual-colour flow cytometry using the cellfit software (Becton Dickinson) (a,b) and Western-blot analysis (c). Representative results of three independent experiments are presented. (d) Quantification of CDC25C expression level by densitomery in the presence (DOX+) or absence (DOXÀ) of doxycycline. Analysis was performed as explained in Figure 3d p53-independent functions of p14 As this specific pattern of protein expression persisted 24 h (Figure 4c ) and even 48 h (data not shown) after the block release, these data are in agreement with the absence of passage through mitosis of the p14 ARF -espressing cells. We noticed that a small proportion of cells was still able to overpass this G 2 arrest. This might be linked to the shorter time (24 h) of p14 ARF induction in synchronization experiments compared to those performed on asynchronous cells.
Taken together, these data with synchronized cells confirmed the results obtained in asynchronous p14 ARF -expressing cells, and demonstrate the ability of p14 ARF to induce a G 2 arrest independently of p53 by preventing cyclin B 1 /CDC2 activation, at least in part through inactivation of CDC25C phosphatase and induction of p21 WAFI .
G 2 arrest precedes apoptosis in p14 ARF expressing cells
Since DNA damage checkpoints may delay cell-cycle progression and lead to apoptosis if the cells are unable to undertake repair (Hartwell and Weinert, 1989; Elledge, 1996; Walworth, 2000) , we asked whether the p14 ARF -induced G 2 arrest might ultimately lead to apoptosis in our cells. Using Hoechst 33352 staining, we observed an apoptotic pattern in 20% of the p14 ARF -expressing cells after 6 or 9 days of doxycyclin induction in clones 19 and 38, respectively. In contrast, this was never detected in uninduced control cells (Figure 5a, b) , as well as in an inducible control clone, even after 15 days of continuous doxycyclin treatment (data not shown). Under the same conditions, the proteolytic activation of procaspase-3 with appearance of the active p12 and p17 fragments as well as PARP cleavage were specifically observed in p14 ARF -induced cells (Figure 5c ). Apoptosis was confirmed in HU-synchronization experiments, since sub-G 1 DNA content, caspase-3 activation and PARP cleavage were specifically detected in p14 ARF -expressing cells 48 h after the block release (Figure 5d ). Overall, these results demonstrate that p14 ARF is also able to induce apoptosis independently of p53. Moreover, as G 2 arrest was clearly observed before apoptosis could take place (Figure 5a, d) , our data suggest that G 2 arrest precedes apoptosis in p14 ARF -expressing cells.
Antitumoral activity of p14 ARF in nude mice is associated with cell-cycle arrest and apoptosis
In order to determine whether the activity associated with p14
ARF expression in cells grown in culture could be reproduced in tumours, H358/Tet-On/p14 ARF clones 19 and 38 or H358/Tet-On cells were injected subcutaneously into immunodeficient nude mice. Of note, the growth kinetics of all cells was very similar (data not shown). As identical results were obtained using both clones, representative data of clone 19 are presented here.
We first tested whether the ability of p14 ARF to induce G 2 arrest and apoptosis is cell lines might influence the tumoral progression. Whereas the uninduced H358/TetOn/ p14 ARF cells (mice drinking water) gave rise to rapid tumour growth, a marked inhibition was observed in mice that received doxycyclin (P ¼ 0.0043) (Figure 6a ). This effect was specific of p14 ARF induction, since growth inhibition was not detected in mice injected with H358/Tet-On cells and those that received doxycyclin (Figure 6a) .
We then asked whether p14 ARF was able to prevent the growth of pre-existing tumours lacking p53. H358/ Tet-On/ p14 ARF cells were injected into nude mice and tumours were allowed to grow until they reach 50-70 mm 3 in volume. At this time, doxycyclin was added or not in their drinking water. A doxycyclin treatment of mice with established H358/Tet-On/p14 ARF tumours caused a highly significant tumoral regression after 80 days of treatment (P ¼ 0.0043) when compared to mice with same tumours but drinking water only or to mice with established H358/Tet-On tumours and drinking doxycyclin (Figure 6b ). This antitumoral activity became statistically significant after 35 days of doxycyclin treatment (P ¼ 0.0043). Immunostaining revealed a clear accumulation of p14 ARF in H358/Tet-On/p14 ARF tumours arising from doxycyclin-treated mice as compared to untreated mice, as well as inhibition of tumor cell proliferation as determined by KI-67 staining and increased apoptosis as detected by active caspase-3 (Figure 7a ) or TUNEL staining (data not shown). When the proliferative index to the apoptotic index was calculated, a lower figure was observed (1.66 versus 4.66) in tumours overexpressing p14 ARF than in those with a physiological level of p14 ARF , in agreement with cell-growth inhibition and apoptosis induction. Furthermore, by using Western blot analyses on whole tumor extracts, we demonstrated a marked downregulation of total CDC25C that was not detected in the control H358/Tet-On tumours (data not shown) and an apparent stable level of CDC2-p Tyr15 (Figure 7b ). However, we could not demonstrate any change in CDC25C-P ser216 or p21 WAFI protein levels, and were unable to detect CDC2-p Thr161 in treated or untreated tumours (data not shown). On the other hand, clear activation of procaspase-3 and PARP cleavage was specifically observed in treated tumours confirming the existence of apoptosis (Figure 7b ). Overall, these results demonstrate the ability of p14 ARF to inhibit cell growth and to induce apoptosis 'in vivo'.
Discussion
Until recently, the ARF tumour-suppressive protein was only ascribed to a well-defined ARF/MDM2/p53 linear pathway. In this model, ARF induces the stabilization and activation of p53 leading to a dual block in G 1 and G 2 phases of the cell cycle and/or cell death (Quelle et al., 1995; Kamijo et al., 1997; Tao and Levine, 1999; Weber et al., 1999 Weber et al., , 2002 Zhang and Xiong, 1999) . In contrast and despite the existence of many contradictory p53-independent functions of p14 ARF B Eymin et al data, it is now well admitted that ARF also acts onto p53-independent pathways to inhibit cell growth. However, the exact nature of the molecular mechanisms involved in these processes is still unclear and the targets remain unknown. In this study, we demonstrate that p14 ARF -expressing cells undergo a G 2 arrest in the absence of functional p53, suggesting that p53 might be necessary for G 1 checkpoint but dispensable for G 2 arrest in response to p14 ARF induction. Consistently, it was previously reported that p53 À/À cells can accumulate in G 2 following DNA damage (Lowe et al., 1993; Fan et al., 1995; Li et al., 1995; Powell et al., 1995) . However, as a prolonged G 2 -M arrest requires p53 (Bunz et al., 1998) , this could explain why p14 ARF induces only a transient G 2 arrest that precedes apoptosis in the absence of active p53. According to our data, the ability of p14 ARF to induce p53-independent apoptosis was recently described in p53-deleted SAOS-2 cells and HCT116 p53 À/À colon cancer cells (Hemmati et al., 2002) . However, cell-cycle analysis was (Weber et al., 2002) . However, in this last paper, all experiments were performed in a 24-48 h time frame and no long-term effects were analysed in contrast to our study. Therefore, as mentioned by the authors, p14 ARF might be able to induce arrest or apoptosis in a p53-negative background once activated over a longer time period.
A key step in regulating the entry of eukaryotic cells into mitosis is the activation of the cyclin B 1 -CDC2 complex (for a review see Takizawa and Morgan, 2000) . Consistently, a strong inhibition of CDC2 activity was associated with G 2 arrest in p14 ARF -expressing cells. When we investigated the mechanisms involved in this inhibition, we observed that CDC2 was markedly hypophosphorylated on Thr161 and apparently hyperphosphorylated on Tyr15. The inhibitory phosphorylations on Tyr15 and Thr14 of CDC2 are counteracted by the CDC25C phosphatase (Kumagai and Dunphy, 1991; Millar et al., 1991; Strausfeld et al., 1991) . In our p14 ARF -expressing cells, the level of CDC25C protein was reduced. Total CDC25C protein level is not significantly affected during cell-cycle progression (Goldstone et al., 2001) in contrast to its phosphorylation status. Therefore, it is unlikely that the specific decrease of CDC25C level following p14 ARF induction could represent the sole consequence of G 2 arrest. Interestingly, as for CDC25A that is downregualted during G 1 checkpoint in response to DNA damage (Mailand et al., 2000) , downregulation of CDC25C has been already reported in response to UVB radiations (Athar et al., 2000) , g radiations (Wang et al., 2000) or infection by adenovirus (Raj et al., 2001) , and related to a decrease of transcription (Wang et al., 2000) or a degradation by the proteasome complex (Raj et al., 2001) . Whether these mechanisms could be implicated in the downregulation of CDC25C protein following p14 ARF induction remains to be determined. On the other hand, overexpression and cytoplasmic accumulation of the CDC25C-P Ser216 inactive form was observed upon p14 ARF induction. Maintenance of the inhibitory phosphorylation of CDC2 on thr14/Tyr15 mediated by a CHK-CDC25C pathway has been previously implicated in a G 2 arrest following DNA damage (Peng et al., 1997; Poon et al., 1997; Rhind et al., 1997; Sanchez et al., 1997) . In such conditions, inactive phosphorylation of CDC25C on Ser216 by CHK1 and CHK2 kinase was observed, allowing binding to the proteins of the 14.3.3 family and preventing CDC2 activation Peng et al., 1997; Sanchez et al., 1997; Graves et al., 2000) . In this way, it would be interesting to study the implication of CHK1 and CHK2 kinase in the p14 ARF -mediated phosphorylation of CDC25C on Ser216. Overall, although further studies are required to assess the role of CDC25C in p14 ARF -mediated G 2 arrest, we propose that p14 ARF might inactivate CDC25C by both downregulating its global expression and increasing its inhibitory phosphorylation on Ser216, both mechanisms cooperating to reinforce the G 2 cellcycle checkpoint. Therefore, although we cannot exclude that Tyr15 (and Thr14) phosphorylations of CDC2 could simply be a result rather than a cause of cyclin B 1 -CDC2 inactivation linked to multiple feedback loops controlling the activity of p34 CDC2 complexes (Poon et al., ) were randomized into two groups drinking either water (&) or 2 mg/ ml doxycyclin (), whereas mice with H358/Tet-On tumours received doxycycline at the same concentration (n). At the indicated times, tumour volumes were measured and the mean7s.d. was calculated for each group (six animals per group). All experiments were performed twice with similar results. Statistical analyses were performed using a nonparametric Mann-Whitney t test. **, Pr0.004 p53-independent functions of p14 ARF B Eymin et al 1997), it is reasonable to assume that inactivation of CDC25C is implicated in the apparent accumulation of inactive CDC2-P Tyr15 upon p14 ARF expression. Concomitantly with CDC25C inactivation, a strong induction of the cyclin-CDK inhibitor p21 WAFI was observed in p14 ARF -expressing cells. Under normal growth conditions, p21 WAFI protein accumulates in G 2 (Dulic et al., 1998; Li et al., 1994) and promotes a pause in late G 2 (Dulic et al., 1998) . However, several studies have also demonstrated the efficient role of p21 WAFI in Figure 7 p14 ARF inhibits cell proliferation and induces apoptosis in nude mice. H358/Tet-On/ p14 ARF cells (clone 19) were subcutaneously injected into nude mice. After 3 weeks, animals were divided into two groups that received water (DoxÀ) or 2 mg/ml doxycyclin (Dox+). After 37 days of treatment, mice were killed, tumours were collected and further processed for immunostaining (a) and Western blot(b) analyses. (a) p14 ARF , kI67 and active (cleaved) caspase-3 labelling. Notice, in treated tumours (Dox+), the strong nuclear staining of p14 ARF associated with a nucleolar pattern in 90% of tumour cells, the lower K167 staining (8.3 versus 14%) reflecting a decrease in cell proliferation and the higher active caspase-3 (6.4 versus 1.5%) staining reflecting an increased apoptosis as compared to untreated tumours (DoxÀ). (b) Western blotting of p14 ARF , cyclin B 1 CDC2, CDC2-P Tyr15 , CDC25C, caspase-3 and PARP in the same tumour samples. Actin was used as a loading control p53-independent functions of p14 ARF G 2 Checkpoint (Agarwal et al., 1995; Niculescu et al., 1998) . Interestingly, Bunz et al. have reported that p21 WAFI is essential to sustain rather than to initiate the G 2 checkpoint after DNA damage in human cells (Bunz et al., 1998) . Despite its low affinity for the cyclin B 1 -CDC2 complex (Harper et al., 1995; Dulic et al., 1998; Winters et al., 1998), p21 WAFI can inhibit CDC2 activity (Yu et al., 1998) and has been recently involved in the inhibition of its activating phosphorylation on Thr161 (Smits et al., 2000) . Whether p21 WAFI affects directly or not the phosphorylation status of CDC2 and mediates some of the p53-indepent effects of p14 ARF remains to be determined. Overall, although we are aware that further studies are required to extend the mechanisms by which p14 ARF inhibits cell growth and to clearly identify direct targets, our data suggest that p14 ARF induces a G 2 arrest independently of p53 by preventing CDC2 activity through both the induction of p21 WAFI and inactivation of CDC25C.
Finally and perhaps the most significant aspect of this work was the finding that p14 ARF conditional expression inhibits tumour growth and induces the regression of p53 À/À human tumours established in nude mice. Importantly, these biological events were associated with an inhibition of cell proliferation as well as an increased apoptosis. Furthermore, although we were unable to detect reproducibly variations in the level of p21 WAFI and CDC25C-P Ser216 , CDC2, CDC2-P Tyr15 , CDC25C, caspase-3 and PARP protein levels varied similarly, 'in vitro' and 'in vivo' strengthening our data on cell lines. Taken together, our results reinforce the notion that p14 ARF can effect pathways and targets other than p53 and demonstrate for the first time that these p53-independent effects can contribute to the tumoursuppressive functions of p14 ARF 'in vivo'. They also predict that the loss of p14 ARF in tumours that have already inactivated p53 might confer an additive deleterious effect on cell growth. Consistently, Weber et al. recently reported that tumours arising in mice lacking ARF and p53 are more aggressive than those in mice lacking either gene alone (Weber et al., 2000) . Furthermore, we previously reported the double inactivation of p14 ARF and p53 in a large proportion of high-grade NE lung tumours (Gazzeri et al., 1998) , the most aggressive lung tumours, a concept that now received full agreement in numerous other cancer types (Sanchez-Cespedes et al., 1999; Esteller et al., 2000; Lindstrom et al., 2000) . Therefore, reintroduction of p14 ARF in these tumours could restore some of the normal checkpoint pathways and thus constitute a major goal of future therapy.
Materials and methods
Cell lines, transfection, proliferation, apoptosis and synchronization assays H358 and H322 human bronchioloalveolar lung carcinoma cell lines were cultured in RPMI-1640 medium (GIBCO, Cergy Pontoise, France), supplemented with 10% (v/v) heat-inactivated FCS, 2 mm l-glutamine and 100 U/ml penicillin/streptomycin in 5% CO 2 at 371C. To ensure exponential growth, cells were resuspended in fresh medium 24 h before transfection. Transient tranasfections were carried out using FUGENE 6 (Roche Diagnostic) according to the manufacturer's protocol. The total amount of DNA used for transfection was held constant by adding empty control vector. In the growth suppression assay, geneticin (G418; 800 mg/ml) was added to the media 48 h post-tansfection and trypan-blue-excluding cells were counted 1 week later. Cell-cycle analysis of transient transfection experiments was performed 4 days after same geneticin treatment. For clonogenic assays using p14 ARF inducible clones, cells were fixed in 100% ethanol at the indicated times, stained with 1% methylene blue in 0.01 m borate buffer, pH 8.5, and optical density was measured at 630 nm after elution in HCI 0.1 N. Evaluation of apoptosis in stable transfectants clones was carried out after 48 h, 72 h, 6 days and 9 days of doxycyclin treatment (1 mg/ml) using Hoechst 33352 staining (5 mg/ml, 30 min at 371C). The percentage of apoptotic cells, identified by their fragmented chromatin, was scored on at least 300 cells using fluorescence microscopy analysis. In the synchronized assays, exponentially H358/Tet-On/P14 ARF clones were pretreated during 24 h with or without 1 mg/ml doxycyclin and further cultured in the presence of 1 mm hydroxyurea (HU) (Sigma). At 24 h after HU treatment, cells were washed twice with PBS and cultured in fresh medium in the presence or absence of doxycyclin for additional indicated times. Cells were then collected and further analysed for DNA content and protein expression. Cell-cycle and Western blot analyses were processed as described below.
Generation of stable p14 ARF inducible clones
Obtention of stable p14 ARF inducible clones was performed using a modified tetracyclin-regulated inducible expression system (Tet-On System, Clontech, Ozyme, Saint Quentin en Yulines, France) according to the manufacturer's protocol. Briefly, H358 cells were transfected in a first round with the pTet-On plasmid, which contains the reverse doxycyclin repressor (rtTA) expression cassette, using TFX-50 (Promega, Charbonnie`res, France) and transferrin (Tfe) (Becton Dickinson, le Pont de Claix, France), and selection of transfectants was performed in the presence of G418 (800 mg/ml). Stable H358/Tet-On clones were screened using the Promega Luciferase Assay System after transient transfections with pTRE-Luc plasmid. A second round of transfection with pTRE-p14 ARF and pTK-Hyg plasmids was then carried out using FUGENE 6. The pTRE-p14 ARF plasmide was constructed by subcloning wild-type p14 ARF cDNA downstream of the Tet-regulated promoter into pTRE plasmid. Double tansfectants were then selected in the presence of hygromycin (200 mg/ml) and geneticin (100 mg/ml), and screened for p14 ARF expression by Western blotting following 48 h of doxycyclin induction (1 mg/ml). Four clones were arbitrarily selected for further experiments.
Antibodies
Monoclonal antibodies (mAbs) used included anti-CDC2/ CDK1 (Ab-3, Oncogene Research), anti-CDC2 p34 (sc-54, Santa-Cruz, Le Perray-en-Yvelines), anti-CDC25C (67211A, Pharmingen), anti-phospho-CDC25C (Ser216) (9D1, Cell Signaling), anti-cyclin B 1 (14541A, Pharmingen), anti-human K167 antigen (clone Ki-67, DAKO) and anti-p21 WAFI (Ab-1, clone EA10, Oncogene Research). Polyclonal antibodies used included anti-actin (20-33, Sigma, Saint Quentin Fallavier, France), anti-caspase-3 (65906E, Pharmingen), anti-human caspase-3 active (R&D System), anti-phospho-CDC2 (Tyr15) (Cell Signaling), anti-phospho-CDC2 (Thr161) (Cell Signal- 
Cell-cycle analysis
Cells were washed twice in PBS and fixed in ice-cold acetone for 5 min at À201C. After two PBS washes, cells were saturated with 2% BSA, 2% goat serum in PBS for 30 min at room temperature and incubated overnight at +41C with gentle rotation in the presence of anti-p14 ARF (Ab-1, 1/200). After extended washes in PBS, Alexat 488 goat anti-rabbit-IgG (H+L) conjugate (2 mg/ml; 1/500, Interchim, Montluc¸on) was added for 30 min at room temperature (RT). Cells were then washed twice in PBS, incubated at 371C for 30 min with 200 U/ ml of RNAse A (Sigma) and then with propidium iodide (10 mg/ml in PBS). Cell-cycle distribution of p14 ARF -expressing cell was determined by dual-colour flow cytometry using the Cellfit software (Becton Dickinson, Grenoble, France).
Indirect immunofluorescence
In all, 50 Â 10 3 cells/well seeded onto 4-well LAB-TEK R . At indicated times, cells were fixed in 4% paraformaldehyde for 5 min at RT, washed three times, saturated in the presence of 2% BSA, 2% goat serum in PBS for 30 min at RT and further incubated with anti-p14 ARF (Ab-1, Oncogene Research; 1/1000) for 2 h. After three PBS washes, Alexat 488 goat anti-rabbit IgG (H+L) conjugate (2 mg/ml; 1/500, Interchim, Montluc¸on) was added for 30 min at RT. Cells were then washed twice in PBS. Normal rabbit IgG at the same concentration as the primary antibody served as a negative control. Cells were counterstained with Hoechst and observed using an Olympus microscope ( Â 20 magnification). Images were captured with a Coolview CCD camera (Photonic Science) and digitally saved using Visilog software.
Immunoblotting
Cells or frozen tumour tissues were lysed in RIPA buffer for 30 min on ice, pelleted and the protein concentration was determined using the Biorad Dc protein assay. Protein (20-40 mg) were then separated by SDS-PAGE in 7-12% gels and electroblotted onto PVDF membranes (Amersham Pharmacia, France). Membranes were incubated overnight at +41C with primary antibody, and proteins were detected using horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and enhanced chemiluminescence detection system (Amersham, Les Ulis, France). To confirm the slight variation of CDC25C expression level, immunoblots were analysed by densitometry using the NIH 1.6 software. Further quantification was performed by normalizing the signals with respect to that of the actin loading control. Results were expressed as a CDC25C/actin ratio that was arbitrarily normalized to a 100% expression level in uninduced cells at each time studied.
For cytoplasmic extracts, cells were incubated for 30 min into an ice-cold buffer containing 250 mm sucrose, 20 mm HEPES-KOH, pH 7.5, 1.5 mm MgCl 2 , 1 mm EDTA, 1 mm EGTA, 1 mm DTT and protease/phosphatase inhibitors. Permeabilization was carried out be serial passages of the cell suspension through a 25G seringue until the obtention of 70-80% trypan-blue-positive cells. Centrifugation at 1700 r.p.m. was then performed for 5 min and supernatants were ultracentrifugated for 30 min at 55 000 r.p.m. in order to obtain the cytosolic fraction.
'In vitro' kinase reaction
Cells were washed three times with PBS, resuspended in lysis buffer (150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 50 mm TrisHCl pH 7.4, 1% Triton Â -100, 0.2 mm Na 3 VO 4 , 0.5% Nonidet P40, 0.1 mm PMSF, 2.5 mg/ml pepstatin, 10 mg/ml aprotinin, 5 mg/ml leupeptin), incubated on ice for 30 min and centrifugated for 20 min at 10 000 r.p.m.. Protein concentration was adjusted to 200 mg in 200 ml NET buffer (150 mm NaCl, 50 mm Tris-HCl pH 7.5, 0.1% NP40, 1 mm EDTA pH 8, 0.25% gelatin, 0.02% sodium azide) supplemented with protease inhibitors before use and incubated overnight at +41C with anticyclin B 1 or anti-CDC2 antibodies. A total of 1 mg of protein A/protein G agarose beads was added to each reaction and sample were incubated for 1 h at +41C with gentle rotation. After two washes in NET buffer, beads were subjected to a final wash in kinase buffer (50 mm Tris-HCl, pH 7.6, 10 mm MgCl 2 , 1 mm DTT). Aliquots (10 ml) were added to 40 ml of kinase buffer containing 50 mm ATP, 10 Ci (g-32 P) ATP (3000 Ci/mmol) and 50 mg of histone H1 and incubated for 30 min at 301C. Samples were boiled in the presence of 50 ml SDS-PAGE loading buffer and subjected to electrophoresis on a 12% polycrylamine gel. CDC2 activity was visualized by autoradiography.
Tumour treatment
'In vivo' experiments were conducted onto 6-weeks-old female swiss nude mice (Iffa Credo, Marcy 1'Etoile, France). In all experiments, 20 Â 10 6 H358/Tet-On/p14 ARF cells were injected subcutaneously into the nude mice and randomized into two groups, one receiving doxycyclin (2 mg/ml) in their drinking water and the second one receiving only water. An additional group of nude mice injected with 20 Â 10 6 H358/Tet-On cells and treated with doxycyclin was used as control. The tumour volumes were measured once a week in two perpendicular diameters and calculated as follows: a Â b 2 Â 0.4, where 'a' and 'b' are the largest and smallest diameters, respectively. All experiments were repeated twice for both 19 and 38 clones. In the tumour uptake assay, doxycyclin was provided immediately after cells injection. Each group was composed of eight animals and difference in tumour volume was assessed using a nonparametric Mann-Whitney t-test. Study of tumour regression was performed on 10 animals per group that received doxycyclin or water when tumour volumes ranged from 50 to 70 mm 3 (about 2 or 3 weeks later). Mice were killed at different times, and tumours were divided into two parts before freezing in order to perform Western blotting or immunohistochemistry. Statistical analysis between the tumour volumes of the different groups was performed using a nonparametric MannWhitney t-test on six animals per group.
Immunohistochemical staining
Immunostaining of p14 ARF , active caspase-3 and K167 was performed on frozen sections, as previously described for p14 ARF and K167 (Gazzeri et al., 1998; Labat-Moleur et al., 1998) and according to the manufacturer's protocol for caspase-3. Briefly, three-step immunohistochemical method was applied on 5 mm thick frozen sections. After fixation, nonspecific binding sites were blocked by incubating the sections with 0.1% (w/v) BSA in phosphate-buffered saline (PBS) for 30 min at room temperature. The sections were subsequently incubated with primary antibodies overnight at 41C, washed in PBS several times and exposed to biotinylated secondary antibodies consisting of either anti-rabbit biotinylated donkey F(ab')2 (1/1000; The Jackson Laboratory; West Grove; PA, USA) or anti-mouse biotinylated donkey F(ab')2 p53-independent functions of p14 ARF B Eymin et al (1/500; The Jackson Laboratory) for 1 h at room temperature. Slides were then washed in PBS and incubated with the streptavidin-biotin-peroxydase complex (1/200; Strept-AB complex; DAKO) for 1 h at room temperature.
The slides were counterstained with Harris' haematoxylin. Normal rabbit or mouse IgG at the same concentrations as the primary antibodies served as negative controls.
